Levels of antibodies against protein C and protein S in pregnancy and in preeclampsia

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 22, Issue 11, 2009, Pages 993-999

  Torricelli, Michela ^a   Sabatini, Laura ^b   Florio, Pasquale ^a   Scaccia, Valentina ^b   Voltolini, Chiara ^a   Biliotti, Giulia ^a   De Bonis, Maria ^a   Petraglia, Felice ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Antibodies against protein C and protein S; Preeclampsia; Pregnancy

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LUPUS ANTICOAGULANT; PROTEIN C; PROTEIN C ANTIBODY; PROTEIN S; PROTEIN S ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPATHOGENESIS; INTRAUTERINE GROWTH RETARDATION; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN FUNCTION; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY;

ADULT; AUTOANTIBODIES; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FETAL GROWTH RETARDATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTERS; PROTEIN C; PROTEIN S; RETROSPECTIVE STUDIES;

EID: 70350292027     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767050903019593     Document Type: Article

References (30)

1. Esmon CT. Protein-C biochemistry, physiology, and clinical implications. Blood 1983;62:1155-1158.
2. Gilabert J, Fernandez JA, Espana F, Aznar J, Estelles A. Physiological coagulation inhibitors (protein S, protein C and antithrombin III) in severe preeclamptic states and in users of oral contraceptives. Thromb Res 1988;49:319-329.
3. Faught W, Garner P, Jones G, Ivey B. Changes in protein C and protein S levels in normal pregnancy. Am J Obstet Gynecol 1995;172:147-150.
4. Nojima J, Kuratsune H, Suehisa E, Futsukaichi Y, Yamanishi H, Machii T, Iwatani Y, Kanakura Y. Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin Chem 2001;47:1008-1015.
5. Heilmann L, Rath W, Pollow K. Hemostatic abnormalities in patients with severe preeclampsia. Clin Appl Thromb Hemost 2007;13:285-291.
6. Ness RB, Sibai BM. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol 2006;195:40-49.
7. Zhou Y, Damsky CH, Chiu K, Roberts JM, Fisher SJ. Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts. J Clin Invest 1993;91:950-960.
8. Tincani A, Rebaioli CB, Frassi M, Taglietti M, Gorla R, Cavazzana I, Faden D, Taddei F, Lojacono A, Motta M, et al. Pregnancy Study Group of Italian Society of Rheumatology. Pregnancy and autoimmunity: maternal treatment and maternal disease influence on pregnancy outcome. Autoimmun Rev 2005;4:423-428.
9. Sabatini L, Torricelli M, Scaccia V, Fineschi D, Pescaglini M, Gasparri L, Florio P, Petraglia F. Increased plasma concentrations of antiprothrombin antibodies in women with recurrent spontaneous abortions. Clin Chem 2007;53:228-232.
10. Committee on Technical Bulletins of the American College of Obstericians and Gynecologists: Hypertension in pregnancy. ACOG Technical Bulletin no 219. Int J Gynaecol Obstet 1996;53:175-183.
11. Yudkin PL, Aboualfa M, Eyre JA, RedmanCW, Wilkinson AR. New birthweight and head circumference centiles for gestational ages 24 to 42 weeks. Early Hum Dev 1987;15:45-52.
12. Mitchell CA, Rowell JA, Hau L, Young JP, Salem HH. A fatal thrombotic disorder associated with an acquired inhibitor of protein C. N Engl J Med 1987;317:1638.
13. Pabinger I, Grafenhofer H. Thrombosis during pregnancy: risk factors, diagnosis and treatment. Pathophysiol Haemost Thromb 2002;32:322-324.
14. Martinelli I, De Stefano V, Taioli E, Paciaroni K, Rossi E, Mannucci PM. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost 2002;87:791-795.
15. Curvers J, Thomassen MC, Rimmer J, Hamulyak K, van der Meer J, Tans G, Preston FE, Rosing J. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. Thromb Haemost 2002;88:5-11.
16. Molino D, De Lucia D, Marotta R, Perna A, Lombardi C, Cirillo M, De Santo NG. In uremia, plasma levels of antiprotein C and anti-protein S antibodies are associated with thrombosis. Kidney Int 2005;68:1223-1229.
17. Lanir N, Aharon A, Brenner B. Haemostatic mechanisms in human placenta. Best Pract Res Clin Haematol 2003;16:183-195.
18. Sargent IL, Germain SJ, Sacks GP, Kumar S, Redman CW. Trophoblast deportation and the maternal inflammatory response in pre-eclampsia. J Reprod Immunol 2003;59:153-160.
19. Redman CW, Sargent IL. Pre-eclampsia, the placenta and the maternal systemic inflammatory response - a review. Placenta 2003;24:S21-S27.
20. Martinuzzo ME, Forastiero RR, Carreras LO. Anti beta 2 glycoprotein I antibodies: detection and association with thrombosis. Br J Haematol 1995;89:397-402.
21. Huppertz B, Kadyrov M, Kingdom JC. Apoptosis and its role in the trophoblast. Am J Obstet Gynecol 2006;195:29-39.
22. Huppertz B, Tews DS, Kaufmann P. Apoptosis and syncytial fusion in human placental trophoblast and skeletal muscle. Int Rev Cytol 2001;205:215-253.
23. Huppertz B, Kaufmann P, Kingdom J. Trophoblast turnover in health and disease. Fetal Maternal Med Rev 2002;13:103-118.
24. Sargent IL, Germain SJ, Sacks GP, Kumar S, Redman CW. Trophoblast deportation and the maternal inflammatory response in pre-eclampsia. J Reprod Immunol 2003;59:153-160.
25. Esmon CT. The impact of the inflammatory response on coagulation. Thromb Res 2004;114:321-327.
26. Fukudome K, Esmon CT. Identification, cloning and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994;269:26486-26491. (Pubitemid 24328474)
27. White B, Schmidt M, Murphy C, Livingstone W, O'Toole D, Lawler M, O'Neill L, Kelleher D, Schwarz HP, Smith OP. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol 2000;110:130-134.
28. Yuksel M, Okajima K, Uchiba M, Horiuchi S, Okabe H. Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-a production by inhibiting activation of both nuclear factor-nB and activator protein-1 in human monocytes. Thromb Haemost 2002;88:267-273.
29. Esmon CT. The protein C pathway. Chest 2003;124:26S-32S.
30. Taylor FB Jr, Peer GT, Lockhart MS, Ferrell G, Esmon CT. Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood 2001;97:1685-1688.